MRD-guided quadruplet therapy and autologous stem cell transplant in newly diagnosed multiple myeloma
Official title: Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma
Funded at Dana-Farber Cancer Inst · NIH-11403916 · Data updated 2026-11-12
This study asks if using a highly targeted blood cancer treatment plan and a stem cell transplant can deepen responses and improve outcomes for people with newly diagnosed multiple myeloma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $79,694 |
| NIH project number | 5P01CA155258-14 |
| Project ID | NIH-11403916 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with newly diagnosed multiple myeloma eligible for quadruplet induction therapy and autologous stem cell transplant.
✕Less likely to help
Patients not eligible for high-intensity therapy or without MRD-targetable disease may see no benefit.
What this research studies
Patients with multiple myeloma may receive a quadruplet induction therapy followed by autologous stem cell transplant to see if deeper remission, measured by ultra-sensitive MRD testing, leads to longer, healthier lives. The study builds on prior work showing MRD negativity is linked to better outcomes and investigates whether adding high-dose therapy after quadruplet induction further improves MRD status and survival. It uses advanced sequencing to measure minimal residual disease at very high sensitivity (10-6) and analyzes how early and sustained MRD negativity relates to clinical results. The trial is conducted through multiple centers including Dana-Farber and CHU-Toulouse, and aims to enroll a large number of patients to answer whether HDT adds value after achieving MRD negativity.
Why it matters
Potential benefit: If successful, patients could achieve deeper remission and longer progression-free survival through an optimized treatment sequence.
How similar studies have gone: Previous work showed MRD status strongly correlates with better outcomes and that quadruplet therapy can achieve high MRD negativity rates.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Corre, Jill — Dana-Farber Cancer Inst
- Study coordinator: Corre, Jill
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.